Related Experiment Video
Updated: Aug 21, 2025
10:21
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
10.1K
Circulating Biomarkers in Hypertrophic Cardiomyopathy
Eldon L Matthia1, Michael L Setteducato1, Mohammed Elzeneini1
1Department of Medicine University of Florida Gainesville FL.
Journal of the American Heart Association
|November 16, 2022
Summary
Circulating biomarkers in hypertrophic cardiomyopathy (HCM) can help doctors diagnose, treat, and predict outcomes for this common genetic heart disease. This review covers key biomarkers related to HCM pathology and their clinical importance.
Area of Science:
- Cardiology
- Genetics
- Biochemistry
Background:
- Hypertrophic cardiomyopathy (HCM) is the most prevalent genetic heart disease.
- Biomarkers, measurable in blood, offer potential for clinical decision-making in HCM.
- Understanding pathological processes in HCM is crucial for effective management.
Purpose of the Study:
- To provide an updated review of circulating biomarkers in hypertrophic cardiomyopathy (HCM).
- To correlate biomarkers with key pathological processes in HCM.
- To discuss the clinical significance of these biomarkers for diagnosis, treatment, and prognosis.
Main Methods:
- Literature review of circulating biomarkers in HCM.
- Categorization of biomarkers based on underlying pathological mechanisms.
- Analysis of clinical utility and significance of identified biomarkers.
Main Results:
- Identified key circulating biomarkers associated with HCM.
- Highlighted biomarkers reflecting wall stretch, myocardial necrosis, fibrosis, inflammation, hypertrophy, and endothelial dysfunction.
- Summarized the clinical relevance of these biomarkers in managing HCM patients.
Conclusions:
- Circulating biomarkers play a vital role in understanding and managing hypertrophic cardiomyopathy.
- These biomarkers can aid clinicians in diagnosis, treatment selection, and outcome prediction.
- Further research into biomarker panels may enhance personalized medicine approaches for HCM.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
37
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
37
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
139
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
139
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
232
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
232
01:29Cardiomyopathy V: Interprofessional Care
27
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
27
01:30Cardiomyopathy II: Dilated Cardiomyopathy
19
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
19
01:29Heart Failure II: Pathophysiology
31
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
31